Photo: AFP / Jens Kalaene
Pharmac is seeking clinical advice on whether weight loss medication should be funded.
New Zealand has the third-highest adult obesity rate in the Organisation for Economic Co-operation and Development (OECD).
One in three people over the age of 15 are classified as obese and one in eight children aged between 2-14.
Pharmac received two applications to fund Wegovy or semaglutide - a GLP-1 receptor agonist for weight loss.
The first was in September, for people with an established cardiovascular disease (such as someone who has had a heart attack or stroke) and a Body Mass Index (BMI) of 27 or higher.
Continue Reading on RNZ
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.